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An entirely plasmid-based reverse genetics (RG) system was recently developed for 25 
rotavirus (RV), opening new avenues for in-depth molecular dissection of RV biology, 26 
immunology, and pathogenesis. Several improvements to further optimize the RG efficiency 27 
have now been described. However, only a small number of individual RV strains have been 28 
recovered to date. None of the current methods have supported the recovery of murine RV, 29 
impeding the study of RV replication and pathogenesis in an in vivo suckling mouse model. 30 
Here, we describe useful modifications to the RG system that significantly improve rescue 31 
efficiency of multiple RV strains. In addition to the 11 RVA segment-specific (+)ssRNAs, a 32 
chimeric plasmid was transfected, from which the capping enzyme NP868R of African swine 33 
fever virus (ASFV) and the T7 RNA polymerase were expressed. Secondly, a genetically 34 
modified MA104 cell line was used in which several compounds of the innate immune were 35 
degraded. Using this RG system, we successfully recovered the simian RV RRV strain, the 36 
human RV CDC-9 strain, a reassortant between murine RV D6/2 and simian RV SA11 strains, 37 
and several reassortants and reporter RVs. All these recombinant RVs were rescued at a high 38 
efficiency (≥80% success rate) and could not be reliably rescued using several recently 39 
published RG strategies (<20%). This improved system represents an important tool and great 40 
potential for the rescue of other hard-to-recover RV strains such as low replicating attenuated 41 
vaccine candidates or low cell culture passage clinical isolates from humans or animals. 42 
IMPORTANCE 43 
Group A rotavirus (RV) remains as the single most important cause of severe acute 44 
gastroenteritis among infants and young children worldwide. An entirely plasmid-based reverse 45 
genetics (RG) system was recently developed opening new ways for in-depth molecular study 46 
of RV. Despite several improvements to further optimize the RG efficiency, it has been reported 47 
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that current strategies do not enable the rescue of all cultivatable RV strains. Here, we 48 
described helpful modification to the current strategies and established a tractable RG system 49 
for the rescue of the simian RRV strain, the human CDC-9 strain and a murine-like RV strain, 50 
which is suitable for both in vitro and in vivo studies. This improved RV reverse genetics system 51 
will facilitate study of RV biology in both in vitro and in vivo systems that will facilitate the 52 
improved design of RV vaccines, better antiviral therapies and expression vectors. 53 
      54 
 55 
INTRODUCTION 56 
     Despite the introduction of multiple safe and effective rotavirus (RV) vaccines such as the 57 
widely licensed Rotarix and RotaTeq vaccines, species A RVs remain the single most important 58 
cause of severe acute gastroenteritis among infants and young children worldwide (1). RVs 59 
are responsible for between 128,000 and 215,000 deaths each year, primarily in developing 60 
countries (2). RVs belong to the Reoviridae family, comprising a variety of icosahedral, 61 
nonenveloped multi-segmented double-stranded (ds) RNA viruses. RVs have three concentric 62 
layers of protein that surround an RNA genome, which contains 11 dsRNA segments encoding 63 
six structural (VP1-VP4, VP6, VP7) and six nonstructural (NSP1-NSP6) proteins (3).  64 
     While our understanding of RV epidemiology, clinical course, pathophysiology, immunology 65 
and replication strategy has increased substantially over the last 40+ years, important questions 66 
about complex and multifaceted processes such as host-range restriction, determinants of 67 
virulence and immune correlates of protection are still poorly understood (3-6). However, due to 68 
the recent introduction of an efficient reverse genetics (RG) system for RVs (7), we now have a 69 
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powerful investigative tool to effectively explore these and other long standing questions 70 
regarding RV biology. Kanai and collaborators first established an entirely plasmid-based RG 71 
system for the simian RV SA11 strain (7). This virus was originally isolated in 1958 (8), is very 72 
well adapted to cell culture, and has been used as a prototype strain in many RV studies over 73 
the ensuing years (9). While it is capable of infecting a variety of animals including primates (10) 74 
and mice (11), it is not highly pathogenic and does not spread efficiently from host-to-host in 75 
experimental animal systems. In the Kanai RG system, 11 plasmids encoding each of the SA11 76 
gene segments are co-transfected with helper plasmids encoding the reovirus fusion-associated 77 
small transmembrane (p10 FAST) protein and the vaccinia virus capping enzymes into BHK-T7-78 
expressing cells. Following an MA104 cell overlay and inoculation of the mixed cell lysates from 79 
the transfected BHK-T7 cells onto fresh MA104 cells, infectious RVs are recovered (7). After 80 
this report, there have been several additional descriptions of the RG system adapted for the 81 
rescue of two human RV strains: KU (12) and Odelia (13). The rescue of several recombinant 82 
viruses based on an SA11 genetic backbone, some carrying heterologous RV gene segments 83 
encoding VP4 and VP7 (14, 15), others carrying engineered segments 5 or 7 with associated 84 
reporter genes have also been reported (7, 16-18). All these reports described some 85 
modifications of the original rescue protocol that purported to further improve the efficiency 86 
and/or utility of the original RG system.  87 
     The suckling mouse is currently the best-established and widely used small animal model 88 
system for studying RV infection in vivo (4, 19, 20). This model faithfully recapitulates several 89 
aspects of RV infection in human infants: suckling mice are highly susceptible to murine RV 90 
infection and develop severe diarrhea following low titer inoculating doses of homologous 91 
murine RVs, while immuno-competent adult mice, like adult humans are more resistant to RV 92 
induced diarrheal disease. Of note, heterologous RVs (non-murine RV such as the SA11 strain) 93 
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can infect suckling and adult mice but replicate poorly, do not cause diarrhea when 94 
administered at low titers, and do not spread efficiently from host to host. In infant mice, cultured 95 
intestinal epithelial cells, and human organoid culture systems an important part of the host 96 
ability to restrict RV replication efficiently is mediated by innate immune response (21-23). 97 
Furthermore, characterization of the replication of murine and non-murine RV strains in the 98 
suckling murine host and in cultured cells has allowed the identification of several highly 99 
effective mechanisms that homologous viruses use to evade the host innate antiviral response 100 
(4, 20, 24-26). 101 
     Murine RVs have proven difficult to adapt to cell culture without losing virulence. In addition, 102 
in general, when adapted they replicate poorly in cell culture, in the range of 1-5X105 plaque 103 
forming units (PFUs)/mL (27, 28) making them difficult to rescue using the current RG 104 
strategies. Many human RV isolates also replicate less robustly than a variety of animal strains 105 
and even some animal RV strains have been difficult to rescue despite their robust replication 106 
ability. For these reasons, we sought to develop a modified, more reproducible and efficient RG 107 
protocol for RV, which relies on the inclusion of a recently described “Chimeric Cytoplasmic 108 
Capping-Prone Phage Polymerase” (C3P3-G1) (29) as well as a genetically modified MA104 109 
cell line. This new protocol enables a more efficient recovery of some human, simian and 110 
murine-like RV strains that had previously proven difficult to rescue using current RG 111 
strategies.             112 
RESULTS 113 
Generation and characterization of an IRF3 and STAT1 defective MA104 cell line.     114 
     Interferons (IFNs) are key components of the innate host defense against many viruses 115 
including RV (4, 24, 30-32). Although MA104 cells are believed to have a blunted IFN response 116 
and this feature plus other characteristics has made them a highly permissive cell substrate for 117 
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RV propagation (33), we reasoned that disarming IFN signaling in MA104 cells might enhance 118 
RV replication and RG recovery rates. We took advantage of the parainfluenza virus 5 (PIV5, 119 
previously SiV5) V protein and the bovine viral diarrhea virus (BVDV) N protease, which target 120 
the signal transducer and activator of transcription 1 (STAT1) (34, 35) and the interferon 121 
regulatory factor 3, also known as IRF3 (36, 37) respectively for degradation. In addition to the V 122 
protein’s ability to prevent the antiviral response by degrading STAT1, its ability to disarm the 123 
RNA sensing pathway by disrupting the RIG-I and MDA-5 activation has been reported (38, 39). 124 
Of note, RIG-I and MDA-5 are known to mount an early interferon response to RV infection (40).  125 
We expressed PIV5 V and BVDV N proteins, either individually or in combination in MA104 126 
cells, as previously described (41). Protein levels of STAT1 and IRF3 were examined by 127 
western blot to confirm functionality-expression of N and V proteins in MA104 stable cell lines 128 
(dual-expressing cells designated as MA104 N*V cells) (Fig 1A).  129 
We next treated the MA104 N*V cells with IFN-α to assess their ability to respond to exogenous 130 
type I IFNs (IFN-I) (Fig 1B). Wild-type (wt) MA104 cells responded to IFN-α treatment, with rapid 131 
phosphorylation of STAT1 (tyrosine 701), followed by induction of canonical interferon-132 
stimulated genes (ISGs) including the Myxovirus resistance protein 1 (MX1) and the interferon-133 
induced transmembrane protein 3 (IFITM3) proteins (Fig 1B). In contrast, there was a complete 134 
loss of STAT1 phosphorylation in MA104 N*V cells (Fig 1B). In addition, neither IFITM3 nor 135 
MX1 levels increased following IFN-α treatment (Fig 1B). Collectively, these data indicated that 136 
the MA104 N*V cells have a diminished response to IFN-α.  137 
Inhibition of IRF3 and STAT1 responses in MA104 cells enhances the replication of 138 
several RV strains.     139 
       We next examined the ability of several human and animal RV strains to replicate in the 140 
wtMA104 as compared to MA104 N, V, or N*V cells. All 5 RV strains tested replicated to 141 
significantly higher virus titers in the MA104 N*V cells (Fig 2A). While some RV strains (e.g. 142 
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RRV and SA11) showed only modest, but significant (p ≤ 0.05) increases, the human CDC-9 143 
strain, a new RV vaccine candidate strain (42), had an almost 10-fold enhancement in viral yield 144 
in the MA104 N*V cells (Fig 2A). For two murine RV strains (ETD and D6/2), we also observed 145 
significant increases in viral titers (~5-fold). Taken together, these findings demonstrate that the 146 
MA104 N*V cells have lower levels of endogenous IRF3 and STAT1 and these lower levels are 147 
associated with significantly enhanced replication capacity of selected human, simian and 148 
murine RV strains. 149 
 In addition to virus titers, we compared RV mRNA levels in wtMA104 and MA104 N*V 150 
infected cells, with or without IFN-α pretreatment (Fig 2B). No difference was observed in RV 151 
NSP5 mRNA levels in MA104 N*V cells in the presence or absence of IFN-α. In contrast, the 152 
replication of an IFN sensitive RV strain (such as UK bovine RV (40) was decreased by 1 Log10 153 
post IFN-α stimulation of wtMA104 cells (Fig 2B). Interestingly, we found that, for the human 154 
CDC-9 strain, pre-treatment of wtMA104 cells with IFN-α (Fig 2B) did not suppress RV 155 
replication. Nevertheless, the level of CDC-9 mRNA was higher (~10X) in the STAT1/IRF3 156 
modified MA104 N*V cells as compared to wtMA104 (Fig 2B). Based on these findings, we 157 
hypothesized that the modified MA104 N*V cells may be a better cell substrate than wtMA104 158 
cells to enhance the RG recovery of some RV strains. 159 
The MA104 N*V cell line enhances the RG recovery of the human rCDC-9 RV. 160 
     Since the MA104 N*V cell line supported higher levels of replication for several RV strains, 161 
we next assessed their ability to enhance RG rescue efficiency. Using the RG system described 162 
by Komoto (12) as a reference, MA104 N*V cells enabled an efficient rescue of the human 163 
CDC-9 strain (10 rescues in 10 attempts). In contrast, when wtMA104 cells were used instead, 164 
only 3 of 10 attempts resulted in the recovery of replication competent rCDC-9 virus. 165 
Additionally, the hard-to-rescue simian RRV strain was not rescued using wtMA104 cells (0 out 166 
of 6 attempts), but when MA104 N*V cells were used, rRRV could be rescued at low efficiency 167 
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(1 out of 3 attempts). These findings indicate that at least for some RV strains, the use of 168 
modified MA104 N*V cells improves the efficiency of the RV RG system.  169 
RNA capping enzyme and T7 polymerase fusion protein further increases RV RG 170 
efficiency.   171 
     With MA104 N*V cells, we were able to rescue rRRV but at a low efficiency. In an attempt to 172 
further improve the RG system, we next added to the system an engineered chimeric protein 173 
(C3P3-G1) consisting of the African swine fever virus NP868R capping enzyme and the T7 174 
DNA-dependent RNA polymerase (29). An earlier version of this plasmid had previously been 175 
shown to enhance the reovirus RG system success rate by approximately 100-fold (43). Such 176 
an increase in viral titer was explained by the capping of mRNA produced with this system, 177 
which enhances protein expression as well as assembly and RNA incorporation into reovirus 178 
virions (43). The inclusion of a cytomegalovirus support plasmid for the African swine fever virus 179 
NP868R capping enzyme in a modified RVA RG system has been reported (16). With this 180 
NP868R-based system, some recombinant rotavirus with a genetically modified segment 7 181 
dsRNA were successfully rescued (16, 18). Nevertheless, the rescue efficiency of murine-like 182 
RV, such rD6/2 like (1) (see below) did not show an improvement using this NP868R-based 183 
system. 184 
We next tested the rescue of the simian RRV strain using the modified Komoto RG system with 185 
or without C3P3-G1 supplementation at a 2:1 ratio along with the other 11 RRV plasmids. 186 
Inclusion of C3P3-G1 substantially increased the efficiency of rRRV rescue from 0/6 to 3/3. 187 
Hence, simply including the C3P3-G1 plasmid to the RV RG protocol significantly (p ≤ 0.05) 188 
increased the efficiency of rRRV recovery in wtMA104 cells.        189 
An RG system for the recovery of recombinant murine-like RVs. 190 
     So far, we have shown that either MA104 N*V cells or C3P3-G1 plasmid alone can 191 
significantly enhance RG rescue of a human or a simian RV strain. To test for potential synergy, 192 
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we attempted the RG rescue of a previously well-characterized, cultivatable and murine virulent 193 
reassortment RV (designated D6/2) derived from a mouse pup co-infected with the non-cell 194 
culture adapted EW strain of murine RV and the RRV strain of simian RV (20, 24). This 195 
reassortant contains 10 of 11 murine EW strain genes and the 4th gene encoding VP4 from 196 
RRV. The D6/2 strain induces diarrhea in suckling pups, transmits between littermates, and 197 
replicates moderately well in cell culture (24). However, despite numerous attempts (>10), D6/2 198 
could not been successfully rescued. We postulated, based on previous genetic analysis (24) 199 
and monoresssortants between SA11 and D6/2 (Supplementary Figure 1), that substituting 200 
SA11 genes 1 and 10 into a molecular D6/2-based recombinant murine RV might possess a 201 
similar virulence phenotype as the naturally occurring murine D6/2 reassortant but be more 202 
amenable to RG rescue.  203 
     Rescue of a rD6/2 like (1) RV; genes 2,3,5,6,7,8,9,11 from the parental wt non-cultivatable 204 
murine EW parental strain, gene 4 from RRV and genes 1 and 10 from SA11, was carried out 205 
as described by the Komoto RG system with modifications, or by including the C3P3-G1, or by 206 
replacing wtMA104 cells with the MA104 N*V cells, or by using both modifications together. We 207 
found that, although the addition of the C3P3-G1 plasmid alone, or the substitution of the 208 
MA104 N*V cells alone, boosted recovery efficiencies, rescue was most efficient, when both, 209 
the C3P3-G1 plasmid and the modified cell line were used together (Table 1). Based on these 210 
results, we propose a new system for the rescue of murine-like RV and other hard-to-rescue RV 211 
strains, as described in detail in the Material and Methods section and is summarized in Figure 212 
3.   213 
Multiple reporter rRVs were rescued using the optimized RG system. 214 
     To provide additional proof-of-concept that this optimized RV RG protocol provides major 215 
advantages over other current systems (in modified versions), we directly compared the rescue 216 
efficiency of this enhanced system to those described by either Komoto et al. or by Kanai et al. 217 
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(7, 12) with modifications. For this purpose, we tested the rescue efficiency of all recombinant 218 
RVs described above, including the simian RRV strain, the human CDC-9 strain, and the rD6/2 219 
like (1) RV. We also included a few more genetically modified rRVs, such as a GFP expressing 220 
RRV (GFP and NSP3 separated by a P2A element on gene segment 7. Fig 5A) and a mono-221 
reassortment of VP4 derived from the bovine RV UK strain on the human CDC-9 backbone 222 
(rCDC-9/UK_VP4). These particular RVs had not been consistently “rescuable” by us or others 223 
(personal communications) using standard RG strategies and served as additional examples 224 
to test whether the improved system allowed the efficient rescue of recombinant RVs bearing 225 
heterologous gene segments or engineered reporter genes.  226 
The modified Kanai and the Komoto protocols rescue recombinant SA11 very efficiently (Table 227 
1). However, rescue frequency of the recombinant human CDC-9 strain was very low using 228 
either the Kanai or Komoto modified protocols (0/2 and 0/8 respectively) and a recombinant 229 
RRV strain was either not isolated (0/2) or isolated only rarely (1/6) using the modified Kanai or 230 
Komoto protocols respectively. Similarly, neither of these modified RG protocols were 231 
particularly efficient for the rD6/2 like (1) RV, when compared to the improved protocol, which 232 
included both the MA104 N*V cells and the C3P3-G1 plasmid (Table 1). In all comparisons, 233 
these rescue improvements were significantly more efficient than the other modified protocols 234 
(P < 0.01).  235 
      To validate the genomic RNA migration patterns of the rescued recombinant RVs, the 236 
dsRNA genomes were isolated and examined by RNA polyacrylamide gel electrophoresis 237 
(PAGE). The dsRNA genome profiles for all recovered recombinant RVs using the optimized 238 
RG system are shown in Fig 4. The dsRNA migration patterns between wt and recombinant 239 
viruses were identical for all the RV strains recovered. For the rD6/2 like (1) RV, the genome 240 
profiles confirmed that segments 1 and 10 originated from SA11 and the remaining nine from 241 
the D6/2 RV. The mono-reassortment containing bovine RV UK strain VP4 on the CDC-9 242 
backbone showed the same migration dsRNA pattern as wtCDC-9, except for segment 4, which 243 
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co-migrated with UK segment 4. Finally, RNA-PAGE was used to identify the modified segment 244 
7 from rRRV-GFP (Fig 4 and 5C), which was additionally confirmed by sequence analysis (data 245 
not shown). Altogether, these findings corroborate the identities of all the recombinant RVs 246 
rescued and document the enhanced efficiency of the improved RG protocol for a wide variety 247 
of RV strains that had proven difficult to rescue using conventional protocols.  248 
       The genetic stability of the rescued recombinant RVs was assessed (Fig 5B and 5C) by 5X 249 
serial passage (p1-p5) in wtMA104 cells and the recombinant progenies from each passage 250 
were titrated by a standard focus forming assay. Virus titers generally increased in the first two 251 
passages (Fig 5B), and then remained stable. The multi-step growth kinetics (Fig 5D) of 252 
recombinant RVs and their plaque sizes (Fig 5E) in wtMA104 cells were also examined and 253 
were not statistically different from their parental strains. Interestingly, the rD6/2 like (1) RV, 254 
which, unlike the D6/2 prototype, harbored 2 genes from SA11, did not show statistically 255 
significant differences in its in vitro growth characteristics compared to the D6/2 parental strain. 256 
But the rRRV-GFP virus that carries an engineered segment 7, although it showed a similar 257 
growth curve to the wtRRV, formed smaller plaques than its parental strain (Fig 5E). The same 258 
phenotype was also observed for other recombinant RVs carrying fluorescent reporters such as 259 
rSA11-GFP, rSA11-mCherry (17) and rSA11-UnaG (16). GFP signals were exclusively 260 
observed in rRRV-GFP infected RV antigen VP6 positive cells (Fig 5F). This rRRV-GFP virus 261 
was stable over 8 passages in wtMA104 cells (Fig 5C). 262 
 263 
Recombinant RVs replicate in the intestine and cause diarrhea in vivo  264 
Finally, to determine whether rRRV and rD6/2 like (1) RV are able to infect mice as their wtRV 265 
counterparts do, the replication, spread, and pathogenesis of these recombinant RV were 266 
studied in an in vivo mouse model (44). Litters of 4 to 5-day-old mice were orally inoculated with 267 
doses of 1X104 PFUs of rD6/2 like (1) or D6/2, or 1X107 PFUs of rRRV or wtRRV. Assessment 268 
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of diarrhea by standard diarrhea scores and intestinal replication as measured by fecal RV 269 
shedding by RT-qPCR (45) were monitored. We observed virtually identical fecal shedding and 270 
diarrhea curves of wtRRV and rRRV following infection (Fig 6A, 6B). 271 
As is shown in Fig 6C and 6D, shedding curves between rD6/2 like (1) vs D6/2 did not show 272 
significant difference. Further, we found that the rD6/2 like (1) RV induce diarrhea and can 273 
spread just as the D6/2 does, since we observed that the non-infected pups (mock) kept in the 274 
same cage as RV infected pups developed diarrhea on 3 to 4 dpi (Fig 6D) and their feces, 275 
collected at day 5-8 pi, was positive for mRNA NSP5 as detected by RT-qPCR. In order to 276 
further characterize the infection in the mouse pups, the dsRNA migration pattern of rD6/2-like 277 
(1) RV was analyzed. RV was isolated from stools collected between day 2-4 of rD6/2-like (1) 278 
RV mice-infected and after 3 serial passages on MA104 cells, a portion of the extracted dsRNA 279 
from the cells was electrophorized (Fig 6E). Taken together, these results support the 280 
conclusion that recombinant RVs exhibit the same in vivo phenotype as their corresponding 281 
wtRV counterparts. As anticipated and consistent with previous characterizations (20, 24, 25) 282 
rD6/2-like (1) was able to efficiently infect mice, induce diarrhea, and spread to uninfected litter 283 
mates in a manner similar or identical to D6/2 RV.  284 
DISCUSSION  285 
In this study, we made several significant modifications of the current RV RG system and 286 
evaluated whether these modifications improved rescue efficiency for certain RV strains. By 287 
adding the recently described C3P3-G1 plasmid (29) along with using genetically modified 288 
MA104 N*V cells with reduced capacity to mount an antiviral IFN response, we developed a 289 
more efficient and consistently successful (≥80%) RV RG protocol that allowed the recovery of 290 
several recombinant RVs that current RG strategies did not efficiently permit. The precise 291 
mechanisms by which the use of C3P3-G1 and of the modified MA104 N*V cell line allowed 292 
enhanced rescue efficiency are not known. Although the full relevance of the CAP structure to 293 
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the RV replication cycle is not well understood, the enhanced capping activity provided for the 294 
C3P3-G1 system seems to be useful. On the other hand, although BHK-T7 constitutively 295 
expresses T7 polymerase, an increased amount of this polymerase provided by transient C3P3-296 
G1 transfection, could also be responsible for higher levels of pT7-RV plasmid transcription. The 297 
disrupted IFN-I response at several levels in the modified MA104 N*V seems likely to be 298 
involved in the capacity of this line to facility the RV rescue. If so, this benefit could be strain 299 
specific, since the ability of different RV strains to effectively counter the IFN response at 300 
different levels is documented (4, 31). 301 
Our findings indicate that the rescued RVs are genetically stable and showed similar replication 302 
phenotypes to their corresponding wtRV parents. In addition, we determined that an RRV 303 
carrying a GFP reporter and a human CDC-9 harboring a heterologous UK VP4 segment can 304 
be efficiently recued and remain genetically stable.   305 
         We established a tractable RG system for the rescue of the simian RRV strain, a prototype 306 
simian RV used as an experimental model for numerous in vivo and in vitro studies 307 
(4, 19, 20, 24). With this improved system, the reliable rescue of recombinant RVs based on an 308 
RRV genetic background is now feasible. In addition, data from suckling mice infection with 309 
wtRRV vs rRRV, demonstrate that rRRV is capable of infecting mice and producing diarrhea in 310 
a manner similar or wtRRV. These rRRV or RRV genetic background viruses, can now be used 311 
in future studies to better understand the genetic basis of systemic RV spread (24, 46), RV 312 
associated biliary disease (47-49), and heterotypic immunity (50).  313 
We also described the rescue via RG of the CDC-9 human RV strain, currently being evaluated 314 
as a potential inactivated human RV vaccine candidate. This strain was first isolated from fecal 315 
specimens and then adapted to grow in Vero cells and it has been shown to be safe, 316 
immunogenic, and effective at inducing immunity against severe RV disease in several animal 317 
models (42, 51). The role of the individual RV proteins as contributors to the protective efficacy 318 
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of CDC-9 can now be directly examined in relevant animal models using selected 319 
monoreassortants (Supplementary Figure 1). Notwithstanding some initial difficulties, we were 320 
able to rescue a recombinant murine-like RV (reassortment RV: genes 2,3,5,6,7,8,9,11 from the 321 
parental wt murine EW strain, gene 4 from RRV and genes 1 and 10 from SA11) which is called 322 
rD6/2 like (1). Prior publications from our lab demonstrated that the host-range restricted murine 323 
RV replication phenotype in the mouse intestine is primarily attributed to gene segments 4 and 5 324 
and does not involve genes 1 and 10 (24). An as we expected this bona fide murine RV was 325 
able to efficiently infect mice, produce diarrhea and spread to uninfected litter mates similar to 326 
as a murine RV.    327 
The new RG capability will now permit us to study the mechanisms and viral determinants of 328 
host range restriction, tissue tropism and systemic spread in mice in much greater detail and 329 
depth and we plan to actively pursue these areas in future studies.  330 
MATERIALS AND METHODS  331 
Cell culture and viruses: The Cercopithecus aethiops epithelial cell line MA104 (ATCC CRL-332 
2378) was grown in Medium 199 (Sigma-Aldrich) supplemented with 10% heat-inactivated fetal 333 
bovine serum (FBS), 100 I.U. penicillin/mL, 100 µg/mL streptomycin and 0.292 mg/mL L-334 
glutamine (complete medium). A Baby Hamster Kidney fibroblast cell line stably expressing T7 335 
RNA polymerase BHK-T7, was kindly provided by Dr. Ursula Buchholz (Laboratory of Infectious 336 
Diseases, NIAID, NIH, USA) and previously described (52). This cell line was cultured in 337 
complete (10% FBS, 100 I.U. penicillin/mL, 100 µg/mL streptomycin and 0.292 mg/mL of L-338 
glutamine) Dulbecco’s modified Eagle’s medium (DMEM) and 0.2 μg/mL of G-418 (Promega) 339 
was added to the complete medium at every other passage. MA104*N, MA104*V and MA104 340 
N*V stable cell lines were generated from MA104 cells as described previously (41) and 341 
cultured in complete medium 199 in the presence of puromycin (5 μg/mL), blasticidin (5 μg/mL) 342 
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and puromycin (3 μg/mL) + blasticidin (3 μg/mL) respectively. Both antibiotics were purchased 343 
from InvivoGen, San Diego, CA. Cells were stimulated with human IFN-α A/D (800 UI/mL) for 30 344 
min or 16 h for either western blot or RV replication studies, respectively. 345 
The wtRV strains used in this study include simian RRV (G3P[3]) (53), and SA11(G3P[2]) (53), 346 
human CDC-9 P50 (G1P[8]) (42), bovine UK (G6P[5]) (53), and the murine reassortant D6/2. 347 
These and other recombinant RVs were propagated in wtMA104 cells as described (54). Prior 348 
to infection, all RV inocula were activated with 5 μg/mL of trypsin (Gibco Life Technologies, 349 
Carlsbad, CA) for 30 min at 37°C.   350 
Plasmids. The simian SA11 plasmid collection: pT7-VP1SA11, pT7-VP2SA11, pT7-VP3SA11, 351 
pT7-VP4SA11, pT7-VP6SA11, pT7-VP7SA11, pT7-NSP1SA11, pT7-NSP2SA11, pT7-352 
NSP3SA11, pT7-NSP4SA11, and pT7-NSP5SA11 as well the three helper plasmids pCAG-353 
D1R, pCAG-D12L and pCAG-FAST-p10 were originally made by Dr. Takeshi Kobayashi 354 
(Research Institute for Microbial Diseases, Osaka University, Japan) and obtained from 355 
Addgene (7). The whole murine pT7-D6/2 plasmid collection and the pT7-UKVP4 were 356 
commercially synthesized (GenScript USA Inc.) The complete simian pT7-RRV plasmid 357 
collection was originally constructed by Dr. Susana Lopez (UNAM, Mexico City, Mexico). The 358 
modified pT7-RRV-NSP3 (see Fig 5A) was engineered following a validated approach 359 
previously described (16, 18). The plasmid constructs for individual genes of RV CDC-9 strain at 360 
passage 11 in MA104 cells were provided by Dr. Baoming Jiang (CDC, Atlanta, USA) (55). The 361 
purification of all the plasmids was performed using QIAGEN Plasmid Miniprep kit per 362 
manufacturer’s instructions. To validate all the new pT7-RV plasmids, a panel of SA11 × CDC-9 363 
or RRV or D6/2 monoreassortant viruses on the strain SA11 genetic background were 364 
generated following the Komoto et al (12) procedure with the following modifications or the 365 
improved RG protocol (see below and Supplementary Figure 1).  366 
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Generation of recombinant rotaviruses: Recombinant RVs were generated as described by 367 
Kanai et al. (7) or Komoto et al. (12) with some modifications. For Kanai protocol 7.5-8.5 × 368 
104 BHK-T7 cells were seeded in 12-well plates, 48 h after cells were cotransfected with 0.4 μg 369 
of either RV rescue plasmid (1-fold), 0.0075 μg of pCAG-FAST, and 0.4 μg of each capping 370 
enzyme expression plasmid using 2 μL of TransITLT1 (Mirus) transfection reagent per 371 
microgram of plasmid DNA. After plasmid transfection, all the transfected cells were processed 372 
as described below. The original Komoto protocol was modified as indicated: confluents 373 
monolayers of BHK-T7 cells, seeded in 12-well plates (see conditions above) were transfected 374 
with 0.4 μg of either RV rescue plasmid (1-fold), with 3-fold increased amounts of the two 375 
plasmids carrying the NSP2 and NSP5 genes (1.2 μg/well) using 3 μL of TransIT-LTI 376 
transfection reagent per μg of plasmid DNA, the transfected BHK-T7 cells were then processed 377 
as described below. 378 
The improved protocol is described in brief: using 1-well of a 12–well plate as a reference, 7.5 379 
X104 BHK-T7 cells were resuspended in 1 mL of complete DMEM (10% heat inactivated SFB, 380 
100 I.U/mL penicillin, 100 µg/mL streptomycin, 0.292 mg/mL) G418-free medium and seeded 381 
into the well. Forty-eight hours later, the medium was replaced by 800 μL of fresh complete 382 
DMEM medium, and then the sub-confluent BHK-T7 monolayer was transfected with the 383 
corresponding transfection mix that contained 125 μL of prewarmed Opti-MEM, 400 ng each of 384 
the 11 RVA pT7 plasmid, except pT7-NSP2 and pT7-NSP5 which were added at 1200 ng, and 385 
800 ng of the plasmid pCMVScript-NP868R-(G4S)4-T7RNAP (C3P3-G1). As transfection 386 
reagents, 14 µL of Trans IT-LTI (Mirus Bio LLC) were used. All the plasmids and transfection 387 
reagents were mixed in a pipet by gently moving it up and down and then incubated at room 388 
temperature for 20 min. After this time, the transfection mixture was added drop by drop to the 389 
medium of BHK-T7 monolayers and then the cells were returned to 37°C.  16-18 hours later, 390 
two washes with FBS-free medium were done after which 800 μL of serum-free DMEM was 391 
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added to the transfected-BHK-T7 cells. Twenty-four hours later, 5X104 wtMA104 (modified 392 
Kanai and Komoto protocols) or MA104 N*V cells (improved protocol) in 200 μL of serum-free 393 
DMEM was added to the well, along with 0.5 μL/mL of porcine pancreatic type IX-S trypsin 394 
(Sigma-Aldrich). MA104 N*V and BHK-T7 cells were co-cultured for 72 hours, after which they 395 
were frozen and thawed three times. To remove cell debris, the lysate was centrifuged at 350 x 396 
g for 10 min at 4°C and then activated with 2.5 μg/mL of trypsin to infect a 3-day old monolayer 397 
of MA104 cells. After 1h of adsorption, the inocula were removed and 1 mL of serum-free 199 398 
medium supplemented with 0.5 μg/mL of trypsin was placed on the cells. MA104 cells were 399 
incubated at 37°C for 5 days or until cytopathic effects were observed (passage 1). We defined 400 
as successfully rescue virus, when MA104 cells infected whit the corresponding RV rescued 401 
passage 1 were positive by immunostaining using an anti-DLPs antibody (see section of focus-402 
forming assay).        403 
Plaque and focus-forming assays: Culture supernatant or virus samples were serially diluted 404 
2 or 10-fold and added to a monolayer of MA104 cells for 1 h at 37 °C. Samples were removed 405 
and replaced with 0.1% agarose (SeaKem® ME Agarose. Lonza) in M199 serum free medium 406 
supplement with 0.5 μg/ mL of trypsin. Cultures for plaque assay were incubated for 2-5 days at 407 
37 °C, then fixed with 10% formaldehyde and stained with 1% crystal violet (Sigma-Aldrich) to 408 
visualize plaques. Cultures for focus forming assay were incubated for 16-18h at 37 °C, then 409 
fixed with 10% paraformaldehyde, permeabilized with 1% tween 20, stained with rabbit 410 
hyperimmune serum to rotavirus (anti-DLPs) produced in our lab and previously described (56) 411 
and anti-rabbit horseradish peroxidase antibody. Viral foci were stained with 3-3′-412 
diaminobenzidine and DAB Chromogen kit (Dako) and enumerated visually. 413 
Immunoblot analysis. Cells were lysed in RIPA buffer [150 mM NaCl, 1.0% IGEPAL® CA-630, 414 
0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0] (Sigma-Aldrich) supplemented with 415 
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protease and inhibitor cocktails [1X] (Thermo Scientific™ Halt™ Protease and Phosphatase 416 
Inhibitor Cocktail.100X). Proteins in cell lysates were resolved in SDS-PAGE (Mini-417 
PROTEAN® TGX™ Precast Gels [4-15%], Bio-Rad) and transferred to membranes 418 
(Nitrocellulose Membrane, 0.45 µm, Bio-Rad). The membranes were blocked by incubation with 419 
5% BSA, 0.1% tween 20 in phosphate-buffered saline (PBS) for 1h at room temperature and 420 
with primary antibodies diluted in PBS containing 5% nonfat dry milk or 5% BSA, followed by 421 
incubation with secondary, species-specific, horseradish peroxidase-conjugated antibodies. The 422 
peroxidase activity was developed using the Clarity ECL substrate, Amersham Hyperfilm, and a 423 
STRUCTURIX X-ray film or Azure Imager, following the manufacturer’s instructions. The blots 424 
were also probed with an anti-GAPDH antibody, which was used as a loading control.  425 
The primaries antibodies and dilutions used were: IRF3 (CST, No. 4302, 1:1000), STAT1 (CST, 426 
No. 14994, 1:1000), Phospho-Stat1, Tyr701 (CST, No. 7649, 1:1000), IFITM3 (Proteintech, No. 427 
11714-1-AP, 1:1000), Mx1 (SCT,No. 37849, 1:1000), GAPDH (Proteintech, No. 60004-1, 428 
1:5000). As secondary antibodies: anti-rabbit (CST, No. 7074,1:5000) or anti-mouse (CST, No. 429 
7076,1:5000) immunoglobulin G horseradish peroxidase-linked antibodies were used.  430 
 431 
RNA gels. Viral dsRNA was extracted with TRIzol (Invitrogen) according the manufacturer’s 432 
protocol and then mixed with Gel Loading Dye, Purple (6X), no SDS (New England Biolabs). 433 
Samples were subjected to PAGE (10%) for 2.5 h at 180 Volts and visualized by ethidium 434 
bromide staining (1 µg/mL) or 18h at 25 mA and silver stained using a previously described 435 
method (57). 436 
Immunofluorescence analysis. MA104 cells were infected for 24h with rRRV-GFP at a MOI of 437 
0.01 FFU, then fixed with 10% paraformaldehyde, permeabilized with 1% tween 20. The cells 438 
were incubated for 1 h at 37 0C temperature with an in-house rabbit anti-DLP antibody diluted at 439 
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1:1000. After, the cells were washed 3x with PBS and then incubated for 1h at 37 0C with 440 
chicken anti-Rabbit IgG, Alexa Fluor 594 (diluted 1:2000 in 0.2% FBS-PBS). Nuclei were 441 
stained with 4′,6-diamidino-2-phenylindole (DAPI). Images were acquired under BZ-X Keyence 442 
fluorescence microscope. 443 
Mice and RV infection. Wild type 129sv mice were originally purchased from the Jackson 444 
Laboratory and maintained as individual in house breeding colonies. 4-5 -day-old pups were 445 
orally inoculated with simian RRV (107 PFUs) or D6/2 (104 PFUs) or recombinant simian RV 446 
RRV strain (107 PFUs) or rD6/2 like (1) (104 PFUs) rescued using the reverse genetics method 447 
described above. Fecal specimens were collected on the indicated days post infection and 448 
subjected to a RT-qPCR based assay measuring RV gene NSP5 levels with standard curves to 449 
determine infectious virus particles per gram of stool samples as described (45). All mice were 450 
housed at the Veterinary Medical Unit of the Palo Alto VA Health Care System. All animal 451 
studies were approved by the Stanford Institutional Animal Care Committee. 452 
Statistical analysis: All experiments, unless otherwise noted, have been repeated at least 453 
three times. The bar graphs are displayed as means ± SEM. Statistical significance were 454 
evaluated using GraphPad Prism 7.0. or the IBM SPSS Statistics Grad Pack 26.  455 
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FIGURE LEGENDS 623 
 624 
Figure 1: MA104 N*V cell line characterization. (A) Representative Immunoblot of cellular 625 
targets of N and V viral proteins in wild type (wt) and modified MA104 cells. Stable cell lines 626 
expressing N, V, or N and V proteins and wtMA104 cell lines were analyzed by immunoblot and 627 
the expression of STAT1 and IRF3 were detected with the indicated antibodies. GAPDH 628 
detection was used as a loading control. (B) wt and MA104 N*V cells were pretreated with or 629 
without 800 UI/mL of IFN-α for 30 min or 16 h and then processed for immunoblot. The 630 
expression of pSTAT1 (Tyr 701), IRF3, STAT1, IFITM3 and Mx1 was detected with the 631 
indicated antibodies. GAPDH detection was used as a loading control. 632 
 633 
 634 
Figure 2: MA104 N*V cells support higher levels of RV replication. (A) MA104 and MA104 N*V 635 
cells were infected with the indicated RV strains at MOI of 1. At 24 hpi, cells were lysed, and 636 
virus titers determined by an immunoperoxidase focus-forming assay. (B) MA104 wt and N*V 637 
cells, pretreated with or without 800 UI/mL of IFN-α for 16 h were infected with indicated RV 638 
strains (MOI=0.01). At the indicated time points, total RNA was harvested and RV NSP5 mRNA 639 
levels were measured by RT-qPCR and normalized to GAPDH. The arithmetic means ± 640 
standard deviations from three (A) or two (B) independent experiments are shown. Statistical 641 
significance was evaluated by student’s t-test. The asterisks indicate significant differences (*p ≤ 642 
0.05; **p ≤ 0.01; ***p ≤ 0.001).   643 
 644 
 645 
Figure 3: Schematic representation of an improved reverse genetics system for RVs recovery 646 























Figure 4: Rotavirus dsRNA genomic profiles by RNA-PAGE. Viral RNA extracted from MA104 650 
cells infected with indicated RVs and then separated on a 10% polyacrylamide gel and stained 651 
by ethidium bromide. The position of segments of interest are marked with red asterisks. The 652 
dsRNA segment numbers are shown in the figure.  653 
 654 
 655 
Figure 5: Recovery of the recombinant RRV (rRRV) and the fluorescent RRV (rRRV-GFP). (A) 656 
pT7 organization of wild type NSP3 and GFP-NSP3 RRV, nucleotide positions are labeled. (B) 657 
Genetic stability of rRRV (blue) and rRRV-GFP (green). The recombinants rotaviruses were 658 
serially passaged 5 times in MA104 cells. Cells were harvest at day 5 post infection or when 659 
complete cytopathic effects were observed, the virus titer was determined by an 660 
immunoperoxidase focus forming assay. (C) Additionally, rRRV-GFP was passaged 8 times in 661 
MA104 cells, RNA viral from all passages (2-8) was extracted and separated on a 10% 662 
polyacrylamide gel and stained by ethidium bromide. The position of engineered segment 7 is 663 
marked with red arrowheads. The segment numbers are shown in the figure. (D) Replication 664 
kinetics of wtRRV, rRRV and rRRV-GFP. Monolayers of MA104 cells were infected with RVs at 665 
an MOI of 0.01 a in the presence of trypsin (0.5 μg/mL) and then were harvest at indicated times 666 
by freezing/thawing. The viral titers were determined by immunoperoxidase focus forming 667 
assay. Results are expressed as the mean viral titer from triplicate experiments. Error bars 668 
shown the SD. (E) Comparison of plaques size. Plaques were generated on MA104 monolayers 669 
and detected at 3 dpi by crystal violet staining. Representative photographs of viral plaques are 670 
shown. The sizes of at least 24 randomly selected plaques from 2 independent plaque assays 671 
were measured using the GraphPad Prism v7 and reported as area on relative units. Mean 672 
values and the standard deviation are shown. Statistical significance was evaluated by student’s 673 
t-test. The asterisks indicate significant differences (ns: not significant, *p ≤ 0.05; **p ≤ 0.01; ***p 674 
≤ 0.001). (F) Subcellular localization of GFP protein in rRRV-GFP infected cells. MA104 cells 675 
were infected with rRRV-GFP at MOI of 0.01. After 24 hpi, infected cells were fixed and 676 
visualized by fluorescence microscopy. Using anti-VP6 polyclonal antiserum and the Alexa 677 
Fluor 594 anti-rabbit IgG, nuclei were stained with DAPI. Scale bar: 50 µm.  678 
 679 
 680 
Figure 6: Characterization of rRVs in an in vivo mice model. Five-day-old 129sv mouse were 681 
orally inoculated with 107 PFUs of simian wtRRV or rRRV (A-B) or 104 PFUs of D6/2 or rD6/2 682 
like (1) RV (C-D). Diarrhea was monitored from days 1 to 8 post infection and fecal specimens 683 
were collected on the indicated dpi and examined by RT-qPCR-based assay measuring RV 684 
gene NSP5 levels with standard curves as a measure of RV shedding per mg of stool. The 685 
numbers of mice in each group are indicated in parentheses. (E) dsRNA genomic profile from 686 
rD6/2 RV was confirmed by RNA-PAGE. The position of segments of interest are marked with 687 
red arrowheads. The segment numbers are shown in the figure.Statistical significance was 688 
evaluated by student’s t-test. The asterisks indicate significant differences (ns: not significant *p 689 
























TABLE LEGENDS 694 
 695 
 696 
Table 1: Comparison of RG rescue frequencies for different RV strains and for modified RV 697 
using Kanai♦, Komoto♦ and the improved RV system including MA104 N*V cells and the C3P3-698 
G1 plasmid. Statistical significance was evaluated by Chi square method. The asterisks indicate 699 
significant differences (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001).   700 
() Numbers in parenthesis: the first number represents the number of successful rescues and the 701 
second one the total number of attempts.  702 


























Table 1: Comparison of RG rescue frequencies for different RV strains and for modified RVs 
using Kanai♦, Komoto♦and the improved RV system including MA104 N*V cells and the C3P3-
G1 plasmid. Statistical significance was evaluated by Chi square method. The asterisks indicate 
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